NanoString Technologies (NSTG) : Traders are bullish on NanoString Technologies (NSTG) as it has outperformed the S&P 500 by a wide margin of 22.12% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.57%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.74% in the last 1 week, and is up 21.46% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 11.55% and the 50-Day Moving Average is 21.54%.The 200 Day SMA reached 34.92%
NanoString Technologies (NASDAQ:NSTG): After opening at $19.5, the stock dipped to an intraday low of $19.3 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $20.283 and the buying power remained strong till the end. The stock closed at $19.98 for the day, a gain of 2.99% for the day session. The total traded volume was 685,675. The stocks close on the previous trading day was $19.98.
NanoString Technologies (NSTG) stock is expected to deviate a maximum of $2.61 from the average target price of $20.6 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $25 and the most muted being $18.
NanoString Technologies, Inc. is engaged in detection, identification and quantification of individual target molecules in a biological sample by attaching a color coded fluorescent reporter to each target molecule of interest. The Company markets its nCounter Analysis System, consisting of instruments and consumables, including its Prosigna Breast Cancer Assay, to academic, government and biopharmaceutical and clinical laboratory customers. The Companys nCounter Analysis System is an automated, multi-application, digital detection and counting system which directly profiles molecules using a barcoding technology. As of December 31, 2014, the Company has an installed base of 264 systems. Prosigna, the Companys molecular diagnostic test, is based on a collection of 50 genes known as the PAM50 gene signature.